Metachromatic Leukodystrophy (MLD)
A rare, inherited disorder of arylsulfatase A (ARSA) deficiency causing progressive demyelination of the central and peripheral nervous systems, with onset ranging from infancy to adulthood.
- ARSA Genetic Testing
- Gene Therapy Access
- Specialist Genetics Review
- Most Common Onset
- Late-Infantile (Before Age 2.5) or Juvenile
- Inheritance
- Autosomal Recessive (ARSA Gene)
- Estimated Incidence
- ~1 in 40,000–160,000 Births
- Advanced Therapies
- Gene Therapy, HSCT
Condition Overview
Metachromatic leukodystrophy (MLD) is a rare inherited disorder caused by deficiency of the enzyme arylsulfatase A (ARSA). This deficiency leads to accumulation of sulfatides, which are toxic to the myelin sheath surrounding nerve fibers in the central and peripheral nervous systems.
MLD presents across a spectrum of ages, with late-infantile (before 30 months), juvenile (30 months to 16 years), and adult-onset forms. Earlier-onset disease tends to progress more rapidly and severely.
Because gene therapy and transplant options are most effective before significant neurological symptoms develop, early diagnosis — including in pre-symptomatic siblings of an affected child — is particularly important in MLD.
Types and Subtypes
MLD is classified by the age symptoms begin, which correlates with disease tempo and severity.
Symptoms and Signs
Symptoms reflect progressive demyelination and vary by the age of onset.
Causes and Risk Factors
MLD results from inherited genetic mutations and is not caused by lifestyle or environmental factors.
Diagnosis and Investigations
Diagnosis combines enzyme testing, genetic confirmation, and imaging to characterize the extent of disease.
Disease Severity and Risk Stratification
MLD is not staged like a cancer, but clinicians stratify patients by age of onset and symptom status to guide treatment decisions.
Standard Treatment Options
Treatment is most effective when started before significant symptoms develop, with options varying by age of onset and disease stage.
Advanced and Emerging Treatment Options
MLD is one of the leukodystrophies with an approved gene therapy option in some regions, alongside ongoing transplant and research approaches.
Gene Therapy
Atidarsagene Autotemcel
An ex vivo lentiviral gene therapy approved in some regions for pre-symptomatic or early-symptomatic late-infantile and early-juvenile MLD.
Cellular Therapy
Hematopoietic Stem Cell Transplant
Used historically, particularly in juvenile and adult forms, to slow central nervous system progression when performed early in the disease course.
Enzyme-Targeted Research
Intrathecal Enzyme Replacement Strategies
Investigational approaches delivering enzyme directly to the central nervous system are being studied for broader patient eligibility.
Biomarkers and Precision Medicine
Biochemical and genetic markers guide diagnosis, eligibility for gene therapy, and monitoring.
When a Second Opinion May Be Important
Given the time-sensitive nature of gene therapy and transplant eligibility, a second opinion can be especially valuable in MLD.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in MLD depend heavily on the age of onset, symptom status at diagnosis, and access to gene therapy or transplant before significant neurological damage occurs.
Supportive Care and Living With MLD
Because MLD affects multiple aspects of neurological function, supportive care plays a central role alongside any disease-modifying treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by MLD navigate report review, coordinate second opinions with leukodystrophy specialists, and explore access to gene therapy and transplant centers, including international options.
Get a free case reviewFrequently Asked Questions
MLD is a rare inherited disorder caused by deficiency of the arylsulfatase A enzyme, leading to progressive damage of myelin in the brain, spinal cord, and peripheral nerves.
Early signs vary by age of onset but often include gait disturbance, loss of motor or cognitive skills, behavioral changes, or speech difficulty.
Yes. It follows an autosomal recessive pattern caused by mutations in the ARSA gene.
Diagnosis involves ARSA enzyme activity testing, urinary sulfatide testing, genetic confirmation, and brain MRI.
Yes, an approved gene therapy exists in some regions for pre-symptomatic or early-symptomatic late-infantile and early-juvenile MLD; eligibility depends on disease stage.
Hematopoietic stem cell transplant has historically been used, particularly in juvenile and adult forms, when performed early in the disease course.
Yes. Adult-onset MLD exists and often presents with psychiatric symptoms or cognitive decline before motor signs appear.
Because gene therapy and transplant are most effective before significant neurological symptoms develop, early or pre-symptomatic diagnosis substantially widens treatment options.
Multidisciplinary teams including neurology, physical and speech therapy, psychiatry, palliative care, and genetic counseling, along with caregiver support groups, can help.
Yes. CancerFax can help review medical and genetic reports, coordinate second opinions with leukodystrophy specialists, and explore access to gene therapy, transplant centers, and international coordination where relevant.
Navigating an MLD Diagnosis?
CancerFax can help you connect with leukodystrophy specialists and explore gene therapy and transplant options.